Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Icecure Medical ( (ICCM) ) has issued an announcement.
On March 17, 2026, IceCure Medical reported record 2025 sales of $3.4 million, including $1.3 million in the fourth quarter, citing strong global commercial momentum for its ProSense® cryoablation system following U.S. FDA clearance in October 2025 for treating low-risk breast cancer. Management highlighted accelerating interest from physicians and hospitals, noting that recent recommendations from the American Society of Breast Surgeons in March 2026 bolster clinical confidence and are driving increased installations and procedure volumes.
The company outlined three major growth drivers: new medical society guidance endorsing cryoablation for select low-risk breast cancer patients, FDA-approved design for its ChoICE post-marketing study enabling 30 hybrid commercial-clinical sites in the U.S., and a March 16, 2026 regulatory submission to Health Canada to expand ProSense®’s breast cancer indication. IceCure also reported record sales in Europe, new placements in leading U.S. hospital networks and regional centers, and expects additional regulatory submissions and reimbursement enhancements that could further strengthen its North American and international market position over the next two years.
The most recent analyst rating on (ICCM) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company that develops minimally invasive cryoablation systems for destroying tumors by freezing, offering an alternative to surgical tumor removal. Its flagship product, the ProSense® cryoablation system, is focused on treating low-risk, early-stage breast cancer and is being commercialized in the U.S. and globally, with growing adoption among hospitals, clinics, and imaging centers.
Average Trading Volume: 270,592
Technical Sentiment Signal: Sell
Current Market Cap: $50.15M
For detailed information about ICCM stock, go to TipRanks’ Stock Analysis page.